Literature DB >> 10989612

Protoporphyrin IX fluorescence kinetics and localization after topical application of ALA pentyl ester and ALA on hairless mouse skin with UVB-induced early skin cancer.

J T van den Akker1, H S de Bruijn, G M Beijersbergen van Henegouwen, W M Star, H J Sterenborg.   

Abstract

In order to improve the efficacy of 5-aminolevulinic acid-based (ALA) photodynamic therapy (PDT), different ALA derivatives are presently being investigated. ALA esters are more lipophilic and therefore may have better skin penetration properties than ALA, possibly resulting in enhanced protoporphyrin IX (PpIX) production. In previous studies it was shown that ALA pentyl ester (ALAPE) does considerably enhance the PpIX production in cells in vitro compared with ALA. We investigated the in vivo PpIX fluorescence kinetics after application of ALA and ALAPE to hairless mice with and without UVB-induced early skin cancer. ALA and ALAPE (20% wt/wt) were applied topically to the mouse skin and after 30 min, the solvent was wiped off and PpIX fluorescence was followed in time with in vivo fluorescence spectroscopy and imaging. At 6 and 12 h after the 30 min application, skin samples of visible lesions and adjacent altered skin (UVB-exposed mouse skin) and normal mouse skin were collected for fluorescence microscopy. From each sample, frozen sections were made and phase contrast images and fluorescence images were recorded. The in vivo fluorescence kinetics showed that ALAPE induced more PpIX in visible lesions and altered skin of the UVB-exposed mouse skin, but not in the normal mouse skin. In the microscopic fluorescence images, higher ALAPE-induced PpIX levels were measured in the stratum corneum, but not in the dysplastic layer of the epidermis. In deeper layers of the skin, PpIX levels were the same after ALA and ALAPE application. In conclusion, ALAPE does induce higher PpIX fluorescence levels in vivo in our early skin cancer model, but these higher PpIX levels are not located in the dysplastic layer of the epidermis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10989612     DOI: 10.1562/0031-8655(2000)072<0399:pifkal>2.0.co;2

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  6 in total

1.  Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy induced clinical erythema.

Authors:  Srivalleesha Mallidi; Sriram Anbil; Seonkyung Lee; Dieter Manstein; Stefan Elrington; Garuna Kositratna; David Schoenfeld; Brian Pogue; Steven J Davis; Tayyaba Hasan
Journal:  J Biomed Opt       Date:  2014-02       Impact factor: 3.170

Review 2.  Preoperative mapping of nonmelanoma skin cancer using spatial frequency domain and ultrasound imaging.

Authors:  Daniel J Rohrbach; Daniel Muffoletto; Jonathan Huihui; Rolf Saager; Kenneth Keymel; Anne Paquette; Janet Morgan; Nathalie Zeitouni; Ulas Sunar
Journal:  Acad Radiol       Date:  2014-02       Impact factor: 3.173

3.  ALA and ALA hexyl ester-induced porphyrin synthesis in chemically induced skin tumours: the role of different vehicles on improving photosensitization.

Authors:  A Casas; C Perotti; H Fukuda; L Rogers; A R Butler; A Batlle
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

4.  Topical application of ALA and ALA hexyl ester on a subcutaneous murine mammary adenocarcinoma: tissue distribution.

Authors:  C Perotti; A Casas; H Fukuda; P Sacca; A Batlle
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

5.  Mapping of oxidative stress responses of human tumor cells following photodynamic therapy using hexaminolevulinate.

Authors:  Lina Cekaite; Qian Peng; Andrew Reiner; Susan Shahzidi; Siri Tveito; Ingegerd E Furre; Eivind Hovig
Journal:  BMC Genomics       Date:  2007-08-13       Impact factor: 3.969

6.  Porphyrin accumulation induced by 5-aminolaevulinic acid esters in tumour cells growing in vitro and in vivo.

Authors:  R G Tunstall; A A Barnett; J Schofield; J Griffiths; D I Vernon; S B Brown; D J H Roberts
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.